Blogs The Glucagon-Like Peptide-1 Receptor (GLP-1R)

The Glucagon-Like Peptide-1 Receptor (GLP-1R)

What is the Glucagon-Like Peptide-1 Receptor (GLP-1R)?

The Glucagon-Like Peptide-1 Receptor (GLP-1R) is a critical player in glucose metabolism and energy homeostasis. As a member of the G protein-coupled receptor (GPCR) family, GLP-1R mediates the effects of glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances insulin secretion in response to food intake. GLP-1R is predominantly expressed in pancreatic β-cells, but it is also found in the brain, heart, gastrointestinal tract, and other tissues, highlighting its diverse physiological roles.

depiction of receptors in a membrane

GLP-1R’s Role in Metabolic Regulation

The functions of GLP-1R are central to maintaining glucose homeostasis and energy balance. When GLP-1 binds to GLP-1R, it triggers a cascade of intracellular signaling events that lead to various physiological outcomes:

Key functions of GLP-1R include:

  • Insulin Secretion: GLP-1R activation enhances glucose-dependent insulin secretion from pancreatic β-cells, thereby lowering blood glucose levels and helping to maintain normal blood sugar levels. (1)
  • Inhibition of Glucagon Secretion: GLP-1R signaling suppresses the release of glucagon, a hormone that raises blood glucose levels by stimulating hepatic glucose production. (1)
  • Appetite Regulation: GLP-1R is expressed in the brain's hypothalamus, where it helps regulate appetite and food intake, contributing to body weight management. (1)
  • Cardiovascular Protection: GLP-1R activation has cardioprotective effects, including improved cardiac function, reduced blood pressure, and enhanced endothelial function. (2)
  • Gastrointestinal Function: GLP-1R modulates gastrointestinal motility and promotes the secretion of gastric enzymes, aiding in digestion and nutrient absorption.

GLP-1R’s Role in Disease and Drug Discovery

Given its integral role in glucose regulation and metabolic health, GLP-1R is a highly attractive target for therapeutic intervention in several metabolic disorders. Research and drug development efforts are focused on leveraging GLP-1R signaling to treat conditions such as:

  • Type 2 Diabetes: GLP-1R agonists, such as exenatide and liraglutide, are already approved for the treatment of type 2 diabetes. These drugs improve glycemic control by enhancing insulin secretion, suppressing glucagon release, and promoting satiety. (3)
  • Weight Management: Due to its effects on appetite regulation, and the FDA approval of Semaglutide (4), also known under the brand names Ozempic and Wegovy, GLP-1R agonists are being explored for weight management in obese individuals. These therapies can help reduce food intake and promote weight loss.
  • Cardiovascular Diseases: The cardioprotective effects of GLP-1R activation make it a promising target for developing treatments for cardiovascular diseases, including heart failure and atherosclerosis.
  • Neurodegenerative Disorders: Emerging research suggests that GLP-1R agonists may have neuroprotective effects and potential applications in treating neurodegenerative diseases such as Huntington’s disease. In fact a study with Exendin-4, an FDA-approved antidiabetic GLP-1R agonist, treatment in mice with mutated human huntingtin protein showed improved motor function, extended survival, regulated glucose, and reduced protein aggregates. (5)

INDIGO's GLP-1R Reporter Assays

Designed to facilitate research into GLP-1R receptor signaling and drug discovery, INDIGO Biosciences’ GLP-1R Reporter Assay offers a comprehensive platform for evaluating GLP-1R activity and screening potential therapeutic compounds. Our assays provide researchers with an all-inclusive luciferase reporter system that includes—in addition to engineered, pre-transfected GLP-1R Reporter Cells—optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, luciferase detection reagent, and a cell culture-ready assay plate. INDIGO Biosciences can also perform the GLP-1R assay in our lab as a service for researchers.

INDIGO’s cell-based reporter assays allow scientists to accelerate the drug discovery process and enable the development of novel therapies for type 2 diabetes, obesity, and cardiovascular diseases. They provide an efficient way to examine a compound for its ability to regulate receptor activity in agonist, inverse-agonist, or antagonist mode using luciferase reporter gene technology. Since the receptor binding controls the expression of the luciferase reporter gene, luciferase activity in the cells can be correlated directly with the activity of the receptor.

INDIGO Biosciences provides comprehensive technical support and expertise to assist researchers in implementing and interpreting GLP-1R reporter assay results, ensuring reliable and reproducible data. Contact us today to learn more about INDIGO's GLP-1R reporter assay kits and our screening capabilities!

 

Works Cited

(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812410/

(2) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10739421/

(3) https://doi.org/10.1016/j.beem.2009.03.008

(4) https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014

(5) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628604/